Angel Chinea, MD
Neurology · Guaynabo, PRNPI 1720029317
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,339,355 of the $1,740,019 with a category attached, or 77.0%. 34 manufacturers reported payments, led by EMD Serono, Inc. at 27.5% of the total. Among neurology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,097 payments — averaging $829.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$479K
- Biogen$402K
- Genentech USA, Inc.$216K
- AbbVie$110K
- Novartis$105K
- Sanofi$83K
- plus $345K from 28 others
Across 194 payments — averaging $59,837 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$10.5M
- Genentech, Inc.$390K
- TG Therapeutics, Inc.$245K
- Sanofi$115K
- EMD Serono, Inc.$74K
- Roche Products Limited$71K
- plus $194K from 8 others
What the payments were for
- Consulting fees$227,28613%
- Speaking & faculty fees$1,339,35577%
- Travel & lodging$111,7666%
- Food & beverage$61,1074%
- Education$5060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 395 | $478,889 |
| Biogen | 439 | $401,873 |
| Genentech USA, Inc. | 235 | $216,087 |
| AbbVie(2 entities) | 91 | $110,002 |
| Novartis | 307 | $104,544 |
| Sanofi | 125 | $83,385 |
| Amgen(2 entities) | 55 | $61,164 |
| AstraZeneca | 53 | $44,286 |
| E.r. Squibb & Sons, L.L.C. | 112 | $43,365 |
| TG Therapeutics, Inc. | 45 | $40,194 |
| Bristol Myers Squibb | 36 | $32,689 |
| Merck Kgaa | 7 | $25,311 |
| Mallinckrodt Hospital Products Inc. | 14 | $23,268 |
| Teva Pharmaceuticals USA, Inc. | 52 | $19,325 |
| Ares Trading SA | 2 | $19,320 |
| Genentech, Inc. | 9 | $9,990 |
| Mallinckrodt Enterprises LLC | 11 | $7,180 |
| Lilly USA, LLC | 7 | $6,975 |
| Banner Life Sciences, LLC | 11 | $6,493 |
| Johnson & Johnson(2 entities) | 3 | $1,722 |
| Alphatec Spine, Inc | 6 | $1,159 |
| Stryker | 6 | $885 |
| ANI Pharmaceuticals, Inc. | 25 | $607 |
| PBG Puerto Rico LLC | 12 | $254 |
| Biohaven Pharmaceuticals, Inc. | 11 | $203 |
| Globus Medical | 2 | $159 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $145 |
| Imperative Care, Inc | 1 | $133 |
| Eli Lilly Export S.A. Puerto Rico Branch | 7 | $126 |
| Medtronic | 1 | $97 |
| Vanda Pharmaceuticals Inc. | 3 | $58 |
| Biocomposites Inc | 1 | $55 |
| Lundbeck LLC | 3 | $50 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,740,019 in reported general payments places this provider in the 95th percentile of 129 neurology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MavencladCladribine | 92 | $6,278,462 |
| Kesimpta PenOfatumumab | 530 | $4,753,904 |
| AubagioTeriflunomide | 209 | $1,944,134 |
| VumerityDiroximel Fumarate | 169 | $1,541,543 |
| GilenyaFingolimod Hcl | 110 | $1,160,202 |
| TecfideraDimethyl Fumarate | 90 | $841,421 |
| AmpyraDalfampridine | 111 | $479,190 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 41 | $341,101 |
| CopaxoneGlatiramer Acetate | 54 | $309,305 |
| MayzentSiponimod | 14 | $208,817 |
| BafiertamMonomethyl Fumarate | 25 | $180,543 |
| Glatiramer Acetate | 72 | $167,759 |
| BetaseronInterferon Beta-1b | 17 | $163,453 |
| TysabriNatalizumab | 11 | $90,960 |
| Dalfampridine ErDalfampridine | 755 | $90,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Mavenclad | $478,889 | $6,278,46292 claims |
| BiogenVumerity, Tecfidera, Tysabri | $401,873 | $2,473,924270 claims |
| SanofiAubagio | $83,385 | $1,944,134209 claims |
| NovartisGilenya, Mayzent | $104,544 | $1,369,019124 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $19,325 | $309,30554 claims |
| AbbVieUbrelvy, Botox, Synthroid | $110,002 | $64,57374 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 129 neurology providers in Puerto Rico.
Other neurology in Guaynabo
- Laura Surillo-DahdahGuaynabo$31K
- Frances Velez LagoGuaynabo$15K
- Yadira Flores MontanezGuaynabo$9K
- Marcos CruzGuaynabo$6K
- Diana BalsalobreGuaynabo$3K
- Janice Vargas RodriguezGuaynabo$2K
- Jose Avila OrnelasCaguas$538K
- Franchesca Fiorito-TorresSan Juan$453K
- Patricia de JesusCaguas$310K
- Mari GarciaSan Juan$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.